Last updated: February 23, 2026
What is the drug identified by NDC 00378-4705?
The National Drug Code (NDC) 00378-4705 corresponds to Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor used primarily for the treatment of various cancers including melanoma, non-small cell lung cancer, and renal cell carcinoma. Manufactured by Bristol-Myers Squibb, Nivolumab's approvals and indications have expanded since its initial FDA approval in 2014.
What is the current market size for Nivolumab?
Market Overview
- Global sales in 2022: approximately $7.8 billion, showing moderate growth from $6.8 billion in 2021.
- U.S. market share: accounts for roughly 60% of global sales, with an estimated revenue of $4.7 billion in 2022.
- Key indications: melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, Hodgkin lymphoma, head and neck squamous cell carcinoma (HNSCC).
Competitive landscape
- Nivolumab faces competition from other PD-1/PD-L1 inhibitors like pembrolizumab (Keytruda) and atezolizumab (Tecentriq).
- Market fragmentation occurs due to multiple therapeutic options per indication, influencing pricing and sales volumes.
What are pricing trends for Nivolumab?
Wholesale Acquisition Cost (WAC)
- The average WAC per 240 mg dose (standard dose for many indications) is approximately $12,000 to $13,000.
- Typical regimen involves 240 mg every 2 weeks or 480 mg every 4 weeks.
Reimbursement and Net Price
- Actual reimbursement varies based on payor negotiations, insurance coverage, and patient assistance programs.
- Estimated net price: approximately $5,000 to $8,000 per dose after discounts, rebates, and negotiations.
Price comparisons
| Parameter |
Nivolumab (Opdivo) |
Pembrolizumab (Keytruda) |
Atezolizumab (Tecentriq) |
| Initial WAC per 240 mg dose |
~$12,200 |
~$13,200 |
~$14,300 |
| Years of market existence |
2014–present |
2014–present |
2016–present |
| Treatment indication overlap |
Yes |
Yes |
Yes |
What are the factors influencing future pricing?
Patent exclusivity
- Nivolumab’s primary patents expire between 2025–2028, subject to extensions and litigation.
Biosimilar and generic entries
- Biosimilar candidates for PD-1 inhibitors are in early-stage development. Full market entry expected post-patent expiration, likely reducing prices by 30-50%.
Market demand
- Growing incidence of cancers treated with immunotherapy drives volume.
- Expansion to earlier lines of therapy and new indications (e.g., first-line NSCLC) can increase sales but put downward pressure on per-unit prices.
Cost management strategies
- Payers emphasize value-based agreements.
- Manufacturer negotiations aim to sustain margins amid increasing competition.
What are the expected price projections?
Short term (2023–2025)
- Steady pricing with slight declines driven by increased competition and biosimilar development.
- Wholesale prices projected to decrease 5–10% annually.
Medium term (2026–2030)
- Potential for significant price reduction of 20–30% following patent expiry and biosimilar availability.
- Discounting, rebates, and managed access programs expected to exert downward pressure.
Long term (post-2030)
- Likely stabilization at lower prices, with biosimilars capturing 40–60% of the market in key indications.
- Total market volume could increase due to expanded indications and broader uptake, partially offsetting reduced unit prices.
Conclusions
- Nivolumab represents a sizable, growing segment within immunotherapy for oncology.
- Pricing is high but projected to decrease progressively, driven by patent expirations and biosimilar competition.
- The current WAC per dose approximates $12,000–$13,000, with net prices falling as discounts grow.
- Market growth depends heavily on expanding indications and improving reimbursement frameworks.
Key Takeaways
- Nivolumab’s global sales are close to $8 billion, with the U.S. accounting for the majority.
- The average current price per dose is about $12,000–$13,000 WAC, with net prices substantially lower.
- Patent expiration between 2025–2028 will likely pressure prices downward.
- Biosimilar development will be a key factor in future pricing dynamics.
- Increasing indications and patient access expand market volume, partially offsetting price declines.
FAQs
1. When do patents for nivolumab expire?
Patent protections are expected to expire between 2025 and 2028, with some extensions possibly granted.
2. How do biosimilar competitors influence nivolumab pricing?
Biosimilars are expected to reduce prices by 30–50%, increasing market share and providing cost savings for payers.
3. What indications are driving the largest sales for nivolumab?
Lung cancer, melanoma, and renal cell carcinoma constitute the primary revenue sources.
4. Are there any government or policy initiatives affecting nivolumab prices?
Price negotiations and value-based agreements in the U.S. and other markets aim to contain costs, especially as biosimilars enter the market.
5. What factors could accelerate price reductions?
Patent expirations, biosimilar approvals, and increased competition from alternative therapies.
References
[1] IQVIA. (2023). Pharmaceutical Market Data & Analysis.
[2] U.S. Food & Drug Administration. (2014). Approval of Nivolumab.
[3] Evaluate Pharma. (2022). Global Oncology Market Report.
[4] Centers for Medicare & Medicaid Services. (2023). Drug pricing and reimbursement policies.
[5] FDA. (2023). Biosimilar Development and Approval.
